Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan for chronic heart failure in hemodialysis patients
ChiCTR2000040750Phase 4Recruiting
- Sponsor
- Blood Purification Center of Peking University International Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacubitril + valsartan in chronic heart failure (CHF), heart failure (HF), left ventricular systolic dysfunction (LVSD) and 1 more, sponsored by Blood Purification Center of Peking University International Hospital. Primary endpoints: NT-proBNP, Left ventricular ejection fraction (LVEF) and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic heart failure (CHF)heart failure (HF)left ventricular systolic dysfunction (LVSD)left ventricular diastolic dysfunction (LVDD)
Beyond the preview
Go deeper on ChiCTR2000040750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040750.